[2][3][4][5] Citing “wins recouping billions of dollars for the federal and state governments,” a February 19, 2015 profile of Mr. Guttman by the Boston Globe's STAT NEWS referred to him as the “Lawyer Pharma Loves to Hate.”[6] Citing a $98 million recovery from Community Health Systems, Inc., Law 360 named Mr. Guttman a “Health Care MVP” and profiled him in a December 1, 2014 article.

[1] Author David Dayen, writing in his Book, Chain of Title (The New Press, 2016) cited Mr. Guttman's work on behalf of “robo-signing” whistleblower, Lynn Szymoniak, noting “he had won some of the largest awards in the history of the False Claims Act; there was really nobody better for the case.” [7] Writing in their book, The Corporate Whistleblower's Survival Guide, (Berrett-Koehler Publishers, Inc., 2011), authors Tom Devine and Tarek F. Massarani wrote that “in settling qui tam litigation, [Mr. Guttman] has aggressively and successfully negotiated for corrective action against public health and safety consequences from prescription drug fraud.” [8] In their book, When Good Companies Go Bad, (ABC CLIO, 2014), authors Donald Beachler and Thomas Shevory profiled Mr. Guttman's off label marketing case against Abbott labs, involving the drug Depakote, which resulted in a $1.6 billion recovery in 2012 for state and federal governments.

[17] That same year, Guttman represented whistleblower Lynn Szymoniak whose qui tam case, involving fraudulent mortgage assignments, was resolved as part of the government's $25 billion settlement with some of the world's largest banks.

[18] In 2013, Guttman was lead counsel in an intervened case by the United States Department of Justice against Pfizer Pharmaceutical involving the kidney-transplant drug Rapamune.

[19] On July 30, 2013, The U.S. Department of Justice announced that Pfizer had agreed to pay $491 million to settle criminal and civil charges stemming from the pharmaceutical company's illegal marketing of Rapamune.

[25] Guttman represented one of the six main whistleblowers in litigation resulting in the government's September 2009, $2.3 billion settlement with Pfizer Pharmaceutical,[26] and he served as counsel in U.S. ex rel.

Guttman served as lead counsel in a series of cases resulting in the recovery of more than $30 million to mid-western meatpackers under the Federal Fair Labor Standards Act.

[32] For the Fall Semester, 2012, Guttman was appointed as an adjunct professor at the Rutgers University Law School, where he taught in the trial program.

[1] Guttman was one of four Emory faculty members who traveled to Shanghai, China in 2013 to participate in a program to train financial fraud prosecutors on the investigation and prosecution of insider trading cases.

[1] Guttman is the author and/or editor of numerous articles, book chapters, and technical publications and his commentary has appeared in Market Watch,[35] Marketplace,[36] American Lawyer Media,[37] AOL Government, Accounting Today, the Austin American-Statesman,[38] and The Jerusalem Post.

[39] His article, Pharmaceutical Regulation in the United States; A Confluence of Influences, was published in Chinese by the Peking University Public Interest Law Journal.